Free Almena, Roth Eli, Dalessandro Marybeth, Hiram Joseph, Scangarella Nicole, Shawar Ribhi, White Scott
Anniston Medical Clinic/Pinnacle Research Group, Anniston, AL, USA.
Skinmed. 2006 Sep-Oct;5(5):224-32. doi: 10.1111/j.1540-9740.2006.05774.x.
Retapamulin is a novel, topical antibacterial of the pleuromutilin class in development for the treatment of secondarily infected traumatic lesions of the skin.
The efficacy, safety, and tolerability of topical retapamulin ointment, 1% for 5 days twice daily was evaluated in 2 identical, randomized, double-blind, double-dummy, multicenter studies vs oral cephalexin, 500 mg twice daily for 10 days, in 1904 patients with secondarily infected traumatic lesions.
Clinical success rates were 89.5% in protocol-adherent patients receiving retapamulin compared with 91.9% for cephalexin (treatment difference, -2.5% [95% confidence interval, -5.4% to 0.5%]). In patients with Staphylococcus aureus or Streptococcus pyogenes at baseline, clinical success was 89.2% (365/409) for retapamulin and 92.6% (63/68) for cephalexin. Safety and tolerability were similar between treatments. Noncompliance (defined as using or taking <80% of doses) was recorded in 8.0% (51/636) of patients taking cephalexin compared with 0.39% (5/1268) of patients receiving retapamulin.
Retapamulin offers a novel, effective, and convenient topical treatment for secondarily infected traumatic lesions.
瑞他帕林是一种新型的截短侧耳素类外用抗菌药物，正在研发用于治疗皮肤继发性感染性创伤。
在两项相同的、随机、双盲、双模拟、多中心研究中，对1904例皮肤继发性感染性创伤患者进行了评估，比较了每日两次外用1%瑞他帕林软膏，连用5天与每日两次口服500 mg头孢氨苄，连用10天的疗效、安全性和耐受性。
接受瑞他帕林治疗且依从方案的患者临床成功率为89.5%，而头孢氨苄为91.9%（治疗差异为-2.5%[95%置信区间为-5.4%至0.5%]）。在基线时感染金黄色葡萄球菌或化脓性链球菌的患者中，瑞他帕林的临床成功率为89.2%（365/409），头孢氨苄为92.6%（63/68）。两种治疗的安全性和耐受性相似。服用头孢氨苄的患者中有8.0%（51/636）记录有不依从（定义为使用或服用剂量<80%），而接受瑞他帕林治疗的患者中这一比例为0.39%（5/1268）。
瑞他帕林为皮肤继发性感染性创伤提供了一种新型、有效且方便的局部治疗方法。
